ORMP · Oramed Pharmaceuticals Inc.

$3.97 -0.20 (-4.80%) At close · Jul 29

Market Cap

$170.66M

40.93M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nadav Kidron	CEO	$439,076	$220,582	—	$569,062	—	$539,131	$1,767,851
Miriam Kidron	Board Member	$305,840	$70,000	—	$299,506	—	$13,354	$688,700
Joshua Hexter	Chief Operating & Business Officer	$190,801	$12,169	—	$351,128	—	$54,735	$608,833
Avraham Gabay	CFO	$130,554	$15,591	—	—	—	$44,912	$191,418

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nadav Kidron	CEO	$419,460	$224,975	—	$398,910	—	$507,750	$1,551,095
Miriam Kidron	Board Member	$267,386	$123,149	—	$211,128	—	$14,503	$616,166
Hilla Eisenberg	CFO	$80,145	$23,859	—	$75,113	—	$11,669	$190,786
Mark Hasleton	VP Business Development	$114,118	—	—	$45,677	—	$18,949	$178,745
Avraham Gabay	CFO	$32,122	—	—	$73,928	—	$9,441	$115,491
Joshua Hexter	Chief Operating & Business Officer	$52,848	—	—	—	—	$9,022	$61,870

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nadav Kidron	CEO	$436,310	$148,795	—	$522,569	—	$442,326	$1,550,000
Miriam Kidron	Board Member	$273,595	$46,614	—	$253,204	—	$13,643	$587,056
Joshua Hexter	Chief Operating & Business Officer	$161,002	$26,895	—	$269,196	—	$50,505	$507,598
Hilla Eisenberg	CFO	$140,518	$9,985	—	$80,810	—	$26,099	$257,412

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Miriam Kidron	Board Member	$254,765	$50,000	$581,932	$359,224	—	$12,775	$1,258,696
Nadav Kidron	CEO	$399,804	$123,000	—	$585,150	—	$45,579	$1,153,533
Hilla Eisenberg	CFO	$87,045	—	—	$112,978	—	$16,133	$200,023

Executive changes

Person	Role	Change	Effective	Filed
Leonard Sank	Board	Resigned	2026-01-01	2025-12-31

Key facts CIK 1176309 CUSIP 68403P203 13F (30d) 10 filings 10 filers Visit website Investor relations